Pharmacokinetics of vitamin E (E,mg/dl) were evaluated in 28 preterm infants following intravenous infusion of doses of dl-tocopherol (~offmann-~a~oche) administered over a period of 8 hours. Blood samples were obtained from a central line immediately prior to, and at 2, 4,6,8,10,12,18,24,48 and 72 hours after E infusion. Dosages were: Group I, (n=4), (BW=1218 5216, GA=29.5 52.6) = 5 mg/kg; Group 11. (n=6),(BW=1091 +165, GA=28.5 21.2) = 10 mglkg; Group 111, (n=7), (BW=1078 5267, GA=27.5 21.2) = 15 mglkg; Group IV, (n=6). (BW= 941 +115, GA=27.5 21.2) = 20 mglkg; Group V, (n=5), (BW=1040 5193, GA=30.8 +3.7) = 30 mglkg. Pharmokinetic parameters were obtained by -independent analysis of E concentration-time profile. Mean +SD values for serum harmonic E half life (~112, hrs), volume of distribution (VD, L/kg), and serum clearance (sc, ml/kg/hr) for the erouDs are:
IV 0.7 +.2 6.2 k3.5 3.5 2.9 3.6 2. Doxapram (Dox), a respiratory stimulant in neonatal apnea, has a short pharmacologic effect (<I hr) despite a reported prolonged plasma t 1/2 (7 hrs). Possible biotransformation to a metabolite (met) previously indistinguishable from Dox by GLC was studied in 6 prematures of bt wgts (1.4120.14), gest. age (31.5~1.02), postnatal age (8.523.01, g i v e n i n c r e m e n t a l D o x i n f u s i o n o f 0,0.1,0.5,1.0,2.5,5.0 mg/kg/h every 20 minutes. Theophylline (theo) has been used in preterm neonates for apnea of prematurity (A&B) and to facilitate extubation. In addition to being a respiratory stimulant, the0 is an airway smooth muscle relaxant. The role of the0 on pulmonary mechanics of preterm neonates with compliant airways was evaluated to define the effect of airway smooth muscle relaxation. Fifteen preterm neonates (632 weeks gestation, 410 days postnatal age) who were administered the0 for A&B or extubation were enrolled in the study. Pulmonary mechanics were determined prior to commencement of the0 and 2-5 days subsequently. Mean the0 level was 8.4 mg/dl). Signals of airflow and transpulmonary pressure, obtained during spontaneous breathing, were analyzed and recorded by the PSDS computer. Mean values for dynamic pulmonary compliance (C. (Dox) has been recently used in the treatment of apnea of the newborn. Currently Dox is given by continuous I.V. low dose infusion; this usually implies a slow onset of action. A bolus infusion as a loading dose should accelerate this onset of action, and in theory repeated boluses could be used for administration. However, increases in blood pressure (BP) have been identified when a continuous I.V. infusion is used. The objective of this study was to define the changes in BP following bolus doses of Dox: 1,2.5, 5 and lOmg/kg given over 1 rnin. Seven lambs were studied at 2 and at 15 oxys of age. After 1 mg/kg, 2 of the 7 two-day old lambs had no change in BP, the 5 others had a transient (<I min) increase of a maximum of 10 mrnllg from baseline; at 15 days of age, 2 had no change in BP, 2 had an increase of 5 to 10 mmHg (<1 min) and 3 had an increase of 10 to 20 mmHg (<2 min). After 2.5 mg/kg a maximum increase of 15 mmHg (<30 sec) was seen in 2 of the 2 day old lambs and in the 15 day old lambs a ~nasi~nu~n increase of 30 mmHg (<1 min) was seen in 1 of the 7 lambs. For doses of 5 and 10 mg/kg the same magnitude of increase was seen hut for a longer duration (5 to 30 minutes). In summary, only a transient mild increase in BP was seen with a rapid (1 rnin) bolus dose of 2.5 mg/kg or less of Dox. The safety of even these apparently small increases in BP is not yet known. Further, the effect of a less rapid infusion rate needs to be determined. The OE response to I.V. bolus infusion of Dox is largely unkown, although Dox is used parenterally in the treatment of apnea of infancy. The objectives of this study were 1) to determine if OE response to Dox changes with postnatal age 2) to characterize the BE response to graded bolus doses of Dox (1 to 10 mg/kg) 3) to partition the peripheral versus the central chemoreceptor response to Dox. Seven intact lambs were studied at 2 and at 15 days of age. Two lambs had carotid body denervation (CBD) at 2 days and were studied at 7 days of age. The animals were studied awake and unsedated. QE was recorded before and continuously for 30 min. after 1 ~ne/ke -, -Dox I.V. bolus. The study was repeated using 2.5, 5 and 10 mg/kg. The BE response was characterized by a diphasic pattern, an early peak and a late plateau. In the 2 day old GE increases rapidly from 550 to 900 ml/kg/min with 1 mg/ kg, returning to near baseline plateau in 10-12 min. With 2.5 mg/kg, the peak 3~ was 1000 ml/kg/min. With 5 and 10 mg/kg, the peak QE did not increase further but the plateau f i~ was shifted to higher OE levels. The same dose response and pattern was seen in the 15 day old lambs. The CBD lambs showed a similar pattern, but the peak response was decreased by more than 50%. Conclusions: 1) no postnatal maturational change wa,s seen in the OE response to Dox 2) Doses >2.5 mg/kg did not increase the peak QE 3) the diminution of the QE by CBD suggests that the peak response is mediated by the peripheral chemoreceptors. AHH. W e have studied urinary metabolite products of caffeine as a means of determining AHH activity following ingestion of small doses of caffeine i n beverages. In a study of 15 adult subjects, a good correlation was found between systemic caffeine clearance and urinary mlar ratios of paraxanthine-7-demethylation products relative to a paraxanthine-8-hydroxylation product (k0.91, p<0.001). In a larger population study, we found: 1. no gender differences i n adults or prepubertal children; 2. no differences between and Caucasians (n=42); [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] showed a higher (p<0.001) mean metabolite ratio than adults (~61); 4. oral contraceptive users (n=9) had lower (p-zO.05) ratio than women not using oral contraceptives (n=30); 5. smokers (n=26) had a higher (p~0.001) ratio than nun-smokers (n=61). In a separate study, an good correlation was found between the urinary metabolite ratio and caffeine clearance as estimated by the 1%-caffeine breath test. Use of caffeine metabolite ratios i n urine lollowing ingestion of the compound i n coffee or cola beverages provides a safe, inexpensive way of monitoring populations for induction of AHH, and for examining the effects of exposure to environmental chemicals early i n life on the ontogeny and regulation of this important class of oxidative drug metabolizing enzymes.
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